1R,2S-Milnacipran

1R,2S-Milnacipran

SCHEMBL8099

CCN(CC)C(=O)[C@]1(c2ccccc2)C[C@@H]1CN

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A2SLC6A4

The experimentally established mechanism targets of 1R,2S-Milnacipran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
SLC6A2 known ✓ P23975 13/20 1.00
SLC6A4 known ✓ P31645 12/20 1.00
SLC6A3 Q01959 5/20 1.00
CYP2D6 P10635 1/20 1.00
HTR2C P28335 1/20 1.00
KDM4E B2RXH2 1/20 0.97
MAPK1 P28482 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
1R,2S-Milnacipran SCHEMBL30083111 1.00 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
Levomilnacipran SCHEMBL12027608 1.00 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
Levomilnacipran SCHEMBL1707471 1.00 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
1R,2S-Milnacipran SCHEMBL5504533 1.00 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
Levomilnacipran SCHEMBL1414867 1.00 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
Milnacipran SCHEMBL114034 1.00 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
Milnacipran SCHEMBL1156056 0.99 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
1R,2S-Milnacipran SCHEMBL4434769 0.99 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
1R,2S-Milnacipran SCHEMBL16241424 0.99 SLC6A2 (0.97) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C
Levomilnacipran SCHEMBL1289763 0.99 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3CYP2D6HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 16263 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121618975-B Time residual processing circuit, correlated multi-sampling method, SS-ADC circuit and chip ANHUI UNIVERSITY (CN) 2026-05-26 CN claimed
US-12624037-B2 Method of treating agitation, aggressive behavior, and impulse control disorder INTRA-CELLULAR THERAPIES, INC. (US) 2026-05-12 US claimed
US-12624036-B2 Method of treating post-traumatic stress disorder INTRA-CELLULAR THERAPIES, INC. (US) 2026-05-12 US claimed
EP-4727538-A2 NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT Tactogen Inc. (US) 2026-04-22 EP claimed
US-20260102372-A1 NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT TACTOGEN INC (US) 2026-04-16 US claimed
US-20260083709-A1 COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA APNIMED INC DELAWARE (US) 2026-03-26 US claimed
EP-4709372-A1 SMALL MOLECULE INHIBITORS OF GLUTAMINASE Leal Therapeutics, Inc. (US) 2026-03-18 EP claimed
US-12544385-B2 Combination drug therapies for CNS disorders JAVED MOHAMMAD (US) 2026-02-10 US claimed
US-20260027337-A1 TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS MORNINGSIDE VENTURE INVESTMENTS LTD (MC) 2026-01-29 US claimed
US-20260027070-A1 METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA APNIMED INC DELAWARE (US) 2026-01-29 US claimed
WO-1997006792-A1 POTENTIATION OF SEROTONIN RESPONSE ELI LILLY AND COMPANY (US) 1997-02-27 WO claimed
EP-0759299-A1 Potentiation of serotonin response ELI LILLY AND COMPANY (US) 1997-02-26 EP claimed
US-5532264-A POTENTIATION OF VENLAFAXINE, MILNACIPRAN AND DULOXETINE TO INCREASE AVAILABLE SEROTONIN, NOREPINEPHRINE AND DOPAMINE IN THE BRAIN BY ADMINISTERING OXYALKYLAMINE DERIVATIVES ELI LILLY AND COMPANY (US) 1996-07-02 US claimed
US-5532244-A Potentiation of drug response ELI LILLY AND COMPANY (US) 1996-07-02 US claimed
US-5532250-A ADMINISTERING A SEROTONIN 1A RECEPTOR ANTAGONIST: ALPRENOLOL, PINDOLOL, PROPRANOLOL, OR TERTATOLOL, WITH FLUOXETINE, VENLAFAXINE, MILNACIPRAN RO DULOXETINE ELI LILLY AND COMPANY (US) 1996-07-02 US claimed
EP-0687472-A2 Potentiation of drug response by a serotonin 1A receptor antagonist ELI LILLY AND COMPANY (US) 1995-12-20 EP claimed
EP-0426712-A1 FILM NOISE REDUCTION BY APPLICATION OF BAYES THEOREM TO POSITIVE/NEGATIVE FILM EASTMAN KODAK COMPANY (US) 1991-05-15 EP claimed
WO-1990001240-A1 FILM NOISE REDUCTION BY APPLICATION OF BAYES THEOREM TO POSITIVE/NEGATIVE FILM EASTMAN KODAK COMPANY (US) 1990-02-08 WO claimed
EP-0294456-A1 TRANSVERSE PRINTING CONTROL SYSTEM FOR MULTIPLE PRINT/CARTRIDGE PRINTER. EASTMAN KODAK CO (US) 1988-12-14 EP claimed
WO-1988004612-A1 TRANSVERSE PRINTING CONTROL SYSTEM FOR MULTIPLE PRINT/CARTRIDGE PRINTER EASTMAN KODAK COMPANY (US) 1988-06-30 WO claimed